Introduction
reaction is catalyzed by a large family of polypeptide GalNAc transferases (GALNTs), consisting of at least 20 members in humans, namely GALNT1 to 14 and GALNTL1 to L6 (5, 6) .
Studies have shown that O-glycans and GALNT genes play critical roles in a variety of biological functions and human disease development. For instance, loss of GALNT1 activity in mice results in bleeding disorder (7) . Risk of epithelial ovarian cancer (8) and coronary artery disease (9) have been associated with single nucleotide polymorphisms of GALNT1 and GALNT2, respectively. GALNT3 expression is a potential diagnostic marker for lung (10) and pancreatic (11) cancers. GALNT6 modifies mucin 1 glycosylation and regulates proliferation of breast cancer cells (12) .
The epidermal growth factor receptor (EGFR) is a promising therapeutic target as its overexpression is associated with various cancers and plays a crucial role in tumor malignancy (13) . Overexpression of EGFR in HCC (14) and up-regulation of EGF in advanced HCC compared with the control liver tissue and early HCC (15) However, the clinical efficacy is still unsatisfactory. Thus, to improve the effect of EGFR-targeted therapies, molecular mechanisms by which EGFR regulates HCC properties should be further investigated.
In HCC, the expression pattern and function of GALNT family have never been reported, although O-glycosylation can regulate multiple cellular properties. Here, we report that GALNT2 is frequently downregulated in HCC. Moreover, GALNT2 modifies EGFR O-glycosylation and activity, and plays a critical role in the malignant phenotype of HCC cells in vitro and in vivo.
Materials and methods

Tissue samples
Post surgery fresh tissue samples were collected from patients receiving treatment at the National Taiwan University Hospital (Supplementary Table S1 ). The tumor samples were taken from the central part of the resected tumor and the paired non-tumor samples were taken 2 cm away from the tumor. For immunohistochemistry, specimens were fixed in 4% (w/v) paraformaldehyde/phosphate buffered saline (PBS).
For RNA extraction, specimens were soaked in RNAlater TM (Qiagen Corp, Tokyo, Table S2 ). Relative quantity of gene expression normalized to GAPDH was analyzed with MxPro Software (Stratagene).
Immunohistochemistry
Paraffin-embedded tissue sections were incubated with anti-GALNT2 polyclonal antibody (1:75, Sigma, St Louis, MO) diluted with 5% non-fat milk/PBS for 16 h at 4°C.
After rinsing twice with PBS, Super Sensitive™ Link-Label immunohistochemistry
Detection System (BioGenex, San Ramon, CA) was used and the specific immunostaining was visualized with 3,3-diaminobenzidine liquid substrate system (Sigma). All sections were counterstained with hematoxylin. Negative controls were performed by replacing primary antibody with control IgG. Tumor cell proliferation was assessed by Ki67 immunoreactivity. Anti-Ki67 rabbit polyclonal antibody (Vector Laboratories, Burlingame, CA) was applied to the slides at 1:500 dilution. Cells with positively stained nuclei were counted in five random fields.
Plasmid construction
RT-PCR was performed for cloning of full-length human GALNT2 (Accession No.
NM_004481) from nontumorous liver total RNA (BD Biosciences, Palo Alto, CA).
The sense primer was 5′-ATGCGGCGGCGCTCGCGGAT-3′, and the anti-sense primer was 5′-CTGCTGCAGGTTGAGCGTGA-3′. The RT-PCR products were cloned into pcDNA3. GALNT2/myc-His fusion gene. The insert was confirmed by DNA sequencing.
Transfection
Overexpression of GALNT2 gene was achieved by transfecting cells with pcDNA3.1/GALNT2/mycHis plasmids using Lipofectamine 2000 (Invitrogen, Life Technologies) according to the manufacturer's protocol. The transfected cells were selected with 600 μg/ml of G418 for 14 days and then pooled for further studies.
siRNA knockdown of GALNT2 expression
SMARTpool siRNA oligonucleotides against GALNT2 and siCONTROL Non-targeting siRNA were synthesized by Dharmacon Research (Thermoscientific, Lafayette, CO). For knockdown of GALNT2, cells were transfected with siRNA using DharmaFECT 4 (Thermoscientific) with a final concentration of 100 nmol siRNA for 48 h.
Western blot analysis
GALNT2 proteins were detected with rabbit anti-GALNT2 polyclonal antibody (Sigma). For detection of EGFR and its downstream signaling molecules, anti-phospho-tyrosine antibody 4G10 (Upstate Biotechnology, Lake Placid, NY) and antibodies against total EGFR, EGFR pY 845, EGFR pY1068, p-Src, Src, p-Shc, Shc, p-AKT, AKT, p-ERK1/2, and ERK1/2 (Cell Signaling Technology, Inc., Beverly, MA) were used. Detection of glycoproteins decorated with Tn antigens was achieved by using biotinylated Vicia villosa agglutinin (VVA , Vector Laboratories) with or without neuraminidase (Sigma) treatment. GAPDH was detected with anti-GAPDH monoclonal antibody (BD Pharmingen, San Diego, CA).
Lectin pull down and immunoprecipitation
To detect the Tn, T, and T/sialyl T on glycoproteins, VVA, peanut agglutinin (PNA), and Jacalin agarose beads (Vector Laboratories) were used, respectively. Briefly, cell lysates (0.5 mg) were incubated with VVA, PNA, or Jacalin agarose beads for 4 h.
Peptide: N-Glycosidase F (PNGaseF, Sigma) was used to remove N-glycans. Protein G sepharose beads (Amersham Pharmacia, Piscataway, NJ) conjugated with 1 μg of anti-EGFR antibody were used in immunoprecipitation. The precipitated proteins were then subjected to western blotting.
Matrigel invasion assay
Cell invasion assays were performed in BioCoat Matrigel Invasion Chambers (Becton Dickinson, Bedford, MA) according to the manufacturer's protocol, as previously described (17) . Briefly, 500 μl DMEM with or without chemoattractants was loaded in the lower part of the chamber and 3×10
4 of transfected cells in 500 μl serum-free DMEM were seeded onto the upper part. Chemoattractants were 10% FBS (PAA Laboratories), 100 ng/ml EGF (Sigma), or 50 ng HGF (Sigma). Cells were allowed to invade the matrigel for 24 h. In some experiments, 70 μM erlotinib (Santa Cruz Biotechnology, Santa Cruz, CA) or dimethyl sulfoxide (DMSO) was included in the upper-chamber medium. The invading cells were fixed and stained with 0.5% (wt/vol) crystal violet (Sigma). The numbers in each well were counted and values are presented as mean ± SD.
Transwell migration assay
The transfected cells (3× 10 4 ) were resuspended in serum-free DMEM and added to the effect of EGFR inhibitor.
Bromodeoxyuridine (BrdU) incorporation and immunofluorescence microscopy
Cells were plated in chamber slides and subjected to serum starvation for 16 h, and treated with 10% FBS (PAA Laboratories), 100 ng/ml EGF (Sigma), or 50 ng HGF (Sigma).for 2 h and then bromodeoxyuridine (BrdU; 10 µM) for 0. 
Internalization of EGFR
Cells were starved for 4 h and then treated with EGF (100 ng/ml) (Sigma) for 10 min at 37°C. The cells were washed with ice cold PBS, fixed, and then immunostained by anti-EGFR (Cell Signaling) and anti-EEA1 (early endosome antigen 1) antibody (Santa Cruz) and counterstained by DAPI (Sigma).
Tumor growth in nude mice
For tumor growth analysis, 6-week-old female BALB/c nude mice 
Statistical analysis
Student's t-test was used for statistical analyses. Data are presented as means ± SDs. We performed paired t-tests for the analysis of paired HCC tissues. Where appropriate, a two-way ANOVA followed by a Bonferroni post hoc test for significance was applied, as indicated in figure legends. P < 0.05 was considered statistically significant.
Results
Expression of GALNT2 is frequently downregulated in human hepatocellular carcinoma
To investigate the potential role of GALNT gene family in HCC, we first analyzed GALNT1-14 and GALNTL1-L6 expression in primary liver tissues by real-time RT-PCR. Among them, only GALNT1 and GALNT2 were found to be highly expressed in the non-tumorous liver tissues (n = 8) (Fig. 1A) . We therefore further analyzed GALNT1 and GALNT2 expression in paired HCC tissues (n = 6). Paired t-tests showed that GALNT2, but not GALNT1, exhibited significant downregulation in HCC tissues (Fig. 1B, lower panel) . Interestingly, GALNT2 downregulation was found in 90.9% (10/11) and 83.3% (10/12) of HCC patients with vascular invasion and recurrence, respectively. Consistent findings of lower expression levels of GALNT2 protein in HCC tissues were observed by western blotting and immunohistochemistry ( Fig. 1C and 1D ). These results suggest that GALNT2 expression is frequently downregulated and associated with invasive properties of HCC.
Stable transfection of Huh7 cells with GALNT2
To investigate the role of GALNT2 in HCC, we first analyzed GALNT2 expression in six HCC cell lines by western blotting. We found that Huh7 expressed lower levels of GALNT2, whereas PLC5 expressed higher levels of GALNT2 in these cell lines ( 
GALNT2 suppresses malignant phenotypes in Huh7 cells
To investigate effects of GALNT2 on malignant phenotypes in Huh7 cells, cell growth, migration, and invasion were analyzed. We found that GALNT2 suppressed FBS-and EGF-induced cell growth (Fig. 3A) . Our data further showed that GALNT2 was able to inhibit FBS-and EGF-induced cell proliferation ( Fig. 3B ), but has no significant effect on apoptosis and cell cycle (data not shown). Furthermore, re-expression of GALNT2 significantly inhibited FBS-and EGF-induced migration and invasion revealed by transwell migration and matrigel invasion assays, respectively ( Fig. 3C and 3D ). In contrast, we did not observe significant changes in cell growth, proliferation, migration, and invasion when cells treated with HGF or under serum free conditions. To further confirm the effects of GALNT2 overexpression on Huh7 cells, GALNT2 overexpression was knocked down by siRNA. Our data showed that the suppressive effects of GALNT2 overexpression were significantly blocked by GALNT2 siRNA but not control siRNA ( Supplementary Fig. S1 ). To know whether EGF plays a role in FBS-induced malignant phenotypes, EGFR inhibitor erlotinib was used to treat mock and GALNT2 stable transfectants. Our data showed that cell growth, migration, and Fig. S2 ). These results suggest that GALNT2 can suppress the malignant behavior of Huh7 cells and the EGF-mediated pathway may be involved in this process.
GALNT2 inhibits tumor growth in nude mice
To investigate the effect of GALNT2 on tumor growth in vivo, Mock and GALNT2 transfected Huh7 cells were subcutaneously xenografted in nude mice. We observed that GALNT2 significantly suppressed tumor volume ( Fig. 4C and 4D ). These results suggest that GALNT2 inhibits HCC tumor cell growth and proliferation in vivo.
GALNT2 modifies glycosylation and activity of EGFR in Huh7 cells
Since we found that GALNT2 can suppress EGF-induced malignant phenotypes, we analyzed whether EGFR glycosylation and activity were modulated by GALNT2 expression. We observed that endogenous EGFRs in HCC cells could not be pulled down by VVA (data not shown). Interestingly, EGFR could be easily pulled down by VVA after neuraminidase treatment (Fig. 5A, upper panel) . In addition, more EGFR molecules were pulled down after the removal of N-glycans by PNGaseF than those without treatment. We also showed that EGFRs could be precipitated by PNA after neuraminidase treatment and pulled down by jacalin without neuraminidase treatment.
To further confirm the presence of O-glycans, EGFR was immunoprecipitated, followed by neuraminidase treatment, and then immunoblotted with VVA. The results obtained consistently show the expression of sialyl Tn structure on EGFRs (Fig. 5A , lower panel), suggesting that short O-glycans, preferentially sialyl Tn, were decorated on EGFRs. Notably, forced expression of GALNT2 enhanced the expression of sialyl Tn on EGFR (Fig. 5B) . To know the effects of glycosylation on EGFR molecules, we analyzed the cell surface expression of EGFR, EGF-induced endocytosis, and EGF-induced dimerization of EGFR. Our data showed that neither the surface expression ( Fig. 5C ) nor EGF-induced dimerization (data not shown) of EGFR was affected by GALNT2. Interestingly, fluorescence microscopy showed that GALNT2 inhibited co-localization of EGFR with EEA1 when cells were treated with EGF ( Fig.   5C ). In addition, endocytosis triggered by Alexa488-EGF was suppressed by GALNT2 ( Supplementary Fig. S3A ). Overexpression of GALNT2 significantly inhibited the elimination of biotinylated EGFR from the cell surface (Supplementary Fig. S3B ).
These results suggest that GALNT2 overexpression inhibits EGF-triggered endocytosis of EGFR. We next examined the effect of GALNT2 on tyrosine phosphorylation of cellular proteins. We found that GALNT2 mainly suppressed tyrosine phosphorylation of proteins located at 175 kDa and 140 kDa (Fig. 5D) . We then investigated whether phosphorylation and activity of EGFR (175 kDa) were modulated by GALNT2. Our data showed that GALNT2 expression inhibited the EGF-induced phosphorylation of EGFR at Y845 and Y1068, as well as the total tyrosine phosphorylation levels revealed by 4G10 mAb (Fig. 5E) .Furthermore, phosphorylation levels of EGFR downstream signaling molecules, including p-Src, p-Shc, pAkt, and p-ERK1/2, also diminished (Fig.   5E ). These results suggest that GALNT2 expression down-regulates EGF-induced phosphorylation of EGFR and, which in turn, suppresses the downstream signaling pathways of EGFR.
Effects of GALNT2 knockdown on HCC cells
To verify the effect of GALNT2 on HCC cells, endogenous GALNT2 expression was knocked down with siRNA. Our data showed that GALNT2 pooled siRNA efficiently inhibited GALNT2 protein expression in PLC5 cells and suppressed the expression of short O-glycans recognized by VVA lectins compared with the control siRNA (Fig. 6A ).
In addition, the knockdown of GALNT2 diminished binding of VVA to neuraminidase-treated EGFR, indicating that less sialyl Tn were present on the EGFR CAN-11-1161 in the GALNT2-knockdowned cells (Fig. 6B) . In these cells, the EGF-induced phosphorylation of EGFR at Y1068 and Y845 was increased (Fig. 6B) , suggesting that EGFRs decorated with less sialyl Tn exhibit higher activity. Moreover, our results showed that knockdown of GALNT2 enhanced EGF-induced cell growth (Fig. 6C) , migration (Fig. 6D), and invasion (Fig. 6E ) in PLC5 cells, whereas no significant changes were observed for cells treated with HGF or under serum free conditions. Surprisingly, PLC5 cells invaded in higher numbers than migrated. In addition, we observed that FBS-induced cell growth, but not migration and invasion, was enhanced by GALNT2 siRNA. Notably, the increase in the EGF-triggered malignant properties induced by GALNT2 knockdown was significantly suppressed by erlotinib, suggesting that EGFR plays a critical role in the phenotypic changes mediated by GALNT2.
To further confirm the effect of GALNT2 on HCC cells, we knocked down GALNT2 expression in another HCC cell line HA22T. Our data showed that knockdown of GALNT2 with siRNA increased EGFR activation but decreased VVA binding to EGFR (Supplementary Fig. S4A ). In addition, EGF-induced cell growth, migration, and invasion were significantly increased by GALNT2 siRNA ( Supplementary Fig. S4B-D) .
These results further demonstrate a role of GALNT2 in regulating the malignant behavior of HCC cells. 
Discussion
We showed that GALNT1 and GALNT2 are the major GALNT enzymes in human liver. Downregulation of GALNT2 was frequently found in primary HCC tissues and associated with vascular invasion and recurrence. Interestingly, GALNT2 modulates the structure of short O-glycans on EGFR. Moreover, GALNT2 could regulate the malignant phenotype and phosphorylation levels of EGFR and its downstream signaling molecules. Here, we show for the first time that GALNT2 can modulate the malignant behavior of HCC cells, and that O-glycosyltransferase is a novel regulator of EGFR function.
Expression of short O-glycans, such as Tn, sialyl Tn, T, and sialyl T, are found in many types of cancer and exploited to develop cancer vaccines (18) . Changes in these structures often alter the function of the cell and its antigenic property, as well as its potential to invade and metastasize (18) . The T antigen expression is associated with lower survival probability and is an independent prognostic factor in colorectal cancer (19) . Sialyl Tn expression is associated with poor clinical outcome in endometrial and colorectal cancer patients (20, 21) . In contrast, the presence of sialyl Tn in keratoacanthoma is associated with tumor regression (22 antibodies or lectins (23, 24). However, the role of short O-glycans in HCC progression and prognosis remains unknown. This study reveals that GALNT1 and GALNT2 are the major GalNAc transferases in liver tissues, and that GALNT2 can modulate the sialyl Tn expression in HCC cells and suppress their malignant properties. Thus, it is of great interest to further investigate the significance of the short O-glycans and the GALNT family in HCC malignancy.
Since there is no consensus sequence for GalNAc addition by GALNTs and O-glycans have never been reported on EGFR, it has long been thought that EGFR carries only N-glycans. This study also showed that neuraminidase-treated EGFR can be pulled down by VVA and PNA. Binding of VVA to the neuraminidase-treated EGFR was enhanced after removal of N-glycans, and GALNT2 enhanced the VVA binding to neuraminidase-treated EGFR. Although the exact sites of O-glycosylation on EGFR require further investigation, our data strongly suggest that EGFR carries short O-glycans. Interestingly, we found that EGF-induced endocytosis of EGFR was suppressed by GALNT2 overexpression, suggesting that changes in O-glycosylation on EGFR could modulate EGFR internalization and thereby regulate its downstream signaling. Indeed, it has been reported that clathrin-mediated internalization is essential for sustained EGFR signaling (25). To our knowledge, this study is for the first time to show that EGFR may express short O-glycans.
We found that GALNT2 can modulate EGF-induced phenotypes in all tested HCC cell lines. In contrast, there is no significant effect for GALNT2 on HGF-triggered phenotypes. These findings suggest that the effect of GALNT2 exhibits selectivity to EGF-, but not HGF-induced phenotypes. We also observed that GALNT2 can significantly modulate 10%FBS-triggered cell growth in HCC cells. Since many substrates for GALNT2 are present in HCC cells, it remains possible that GALNT2 mediates its effects through other receptors in addition to EGFR. EGFR inhibitors prevent the development of HCC in animal models (26) and erlotinib has shown some activity in the treatment of human HCC (16, 27) . Sorafenib, a multikinase inhibitor, has been demonstrated to provide a significant survival benefit for patients with advanced HCC (28). However, the efficacy of these agents still remains to be improved. So far, no single target is identified to play the major role in HCC progression, suggesting that 
